Shanghai Haohai Biological Technology Co., Ltd.

Equities

6826

CNE100001W69

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:35 2024-04-19 am EDT 5-day change 1st Jan Change
37.4 HKD -3.86% Intraday chart for Shanghai Haohai Biological Technology Co., Ltd. -3.61% -7.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5% MT
Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Haohai Biological Forecasts Up to 138% Boost in 2023 Profit MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023 CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023. CI
Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee CI
Haohai Biological Technology's Q3 Profit Rises 34%; Hong Kong Shares Jump 5% MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023. CI
Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 1,538,461 shares, representing 0.9% for CNY 200 million, under the auhtorization approved on September 15, 2023. CI
Shanghai Haohai Biological Technology to See Rise in January-September Profit MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023 CI
Shanghai Haohai Biological Technology's Profit Surges 188.9% in H1; Shares Up 3% MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. authorizes a Buyback Plan. CI
Shanghai Haohai Biological to Buy Remaining Stake in Medical Aesthetics, Cosmetology Business MT
Shanghai Haohai Biological Technology Co., Ltd. entered into the equity transfer agreement to acquire 36.3636% stake in OHMK Medical Technology Co., Ltd. from Tianjin Huacan Enterprise Management Consulting Partnership, Shanghai Ermei Enterprise Management Consulting Partnership, Yuan Yibing, Lian Songyong and Chen Guangfei for approximately CNY 150 million. CI
Shanghai Haohai Biological Technology’s H1 Profit to See Up to 210% Boost MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. Announces Final Cash Dividend for the Year Ended December 31, 2022 CI
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. Announces Ordinary Final Dividend for the Year Ended December 31, 2022 CI
Shanghai Haohai Biological Technology's 2022 Profit Halves MT
Chart Shanghai Haohai Biological Technology Co., Ltd.
More charts
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
34.57 CNY
Average target price
65.08 CNY
Spread / Average Target
+88.26%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 6826 Stock
  4. News Shanghai Haohai Biological Technology Co., Ltd.
  5. Shanghai Haohai Biological Technology : Drops 10% as 2020 Net Profit Slumps 38%